In the pharmaceutical field, in order to make your investments in Research and Development profitable, the industrial property strategy is a priority which must be based on two pillars: the construction and evaluation of your patent portfolio around each of your projects; the monitoring and management of risks with regard to third party titles with a view to the exploitation of your future products.
Our support aims to maximise the lifespan, geographical scope and value of your assets by filing active ingredient patents and to consolidate your portfolio with complementary patents (formulations, processes).
This strategy must be developed in line with the progress of experimental data/clinical trials and regulatory provisions.
In the field of drugs and medical devices, the constraints of marketing authorisations are closely linked to industrial property, since this long regulatory path may allow you to trigger mechanisms for extending your rights, such as supplementary protection certificates (SPC) and pediatric extensions.
Regimbeau has a team of experts in the fields of organic chemistry, biochemistry and pharmaceuticals: active ingredients, organic synthesis processes, galenic formulations, new therapeutic uses, diagnostics and medical imaging.
A dedicated team is set up for each project, based on the respective expertise and experience of our Counsels, who are aware of your challenges and constraints and will be able to assist you in securing and creating value around your projects at each stage of their development.
Our experience and skills are recognised in the field of industrial property litigation regularly faced by players in your field (pioneering companies or generic drugs manufacturers). We operate both in France and internationally to assert your rights or defend you against competitors.